NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells.

ABSTRACT:

Background

Medulloblastoma (MB) is the most common pediatric malignant brain tumor. Despite current therapies, the morbidity and recurrent risk remains significant. Neuropilin-1 receptor (NRP1) has been implicated in the tumor progression of MB. Our recent study showed that NRP1 inhibition stimulated MB stem cells differentiation. Consequently, we hypothesized that targeting NRP1 in medulloblastoma could improve current treatments.

Methods

NRP1 inhibition with a novel peptidomimetic agent, MR438, was evaluated with radiotherapy (RT) in MB models (DAOY, D283-Med and D341-Med) in vitro on cancer stem-like cells as well as in vivo on heterotopic and orthotopic xenografts.

Results

We show that NRP1 inhibition by MR438 radiosensitizes MB stem-like cells in vitro. In hetero

SUBMITTER: Douyere M 

PROVIDER: S-EPMC9714111 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature